Brief: Applied Therapeutics Genetic Disorder Drug At-007 Receives Orphan Medicinal Product Designation In Europe

Applied Therapeutics

25/05/2023 13:25

May 25 (Reuters) - Applied Therapeutics Inc  APLT.O :
    * GOVORESTAT (AT-007) RECEIVES ORPHAN MEDICINAL PRODUCT
DESIGNATION FROM EMA FOR TREATMENT OF SORD DEFICIENCY
    * APPLIED THERAPEUTICS-EMA DESIGNATION REFLECTS HIGH UNMET
NEED IN
SORD DEFICIENCY,BENEFIT OF GOVORESTAT TREATMENT IN REDUCING
TOXIC SORBITOL LEVELS

Source text for Eikon:  ID:nGNXchnbpj 
Further company coverage:  APLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))